Blepharoconjunctivitis: a side effect of 13-cis-retinoic acid therapy for dermatologic diseases.
Blepharoconjunctivitis developed as a side-effect of treatment of patients with basal cell carcinomas, keratinizing dermatoses, and cystic acne with oral 13-cis-retinoic acid. Forty-two of the 97 dermatologic patients had signs and symptoms of blepharoconjunctivitis that were dose related and abated one week after discontinuation of the medication. About half of the patients had a history of similar symptoms prior to treatment. Staphylococcus aureus was present in eye cultures of 73% to 79% of the patients, whether symptomatic or not. Patients whose clinical appearance was that of staphylococcal blepharoconjunctivitis and whose cultures grew S aureus were successfully treated with topical erythromycin ointment to the lids even while being treated with the 13-cis-retinoic acid.
D000152:Acne Vulgaris / Q000188:drug therapy; D001762:Blepharitis / Q000139:chemically induced* / Q000188:drug therapy; D002280:Basal Cell Carcinoma / Q000188:drug therapy; D003231:Conjunctivitis / Q000139:chemically induced* / Q000188:drug therapy; D004917:Erythromycin / Q000627:therapeutic use; D005141:Eyelid Diseases / Q000139:chemically induced*; D006801:Humans; D007642:Keratosis / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D014212:Tretinoin / Q000009:adverse effects* / Q000627:therapeutic use
D014212:Tretinoin; D004917:Erythromycin